Pentoxifylline prevents loss of PP2A phosphatase activity and recruitment of histone acetyltransferases to proinflammatory genes in acute pancreatitis.

Abstract

Mitogen-activated protein kinases (MAPKs) are considered major signal transducers early during the development of acute pancreatitis. Pentoxifylline is a phosphodiesterase inhibitor with marked anti-inflammatory properties through blockade of extracellular signal regulated kinase (ERK) phosphorylation and tumor necrosis factor alpha production. Our aim was to elucidate the mechanism of action of pentoxifylline as an anti-inflammatory agent in acute pancreatitis. Necrotizing pancreatitis induced by taurocholate in rats and taurocholate-treated AR42J acinar cells were studied. Phosphorylation of ERK and ERK kinase (MEK1/2), as well as PP2A, PP2B, and PP2C serine/threonine phosphatase activities, up-regulation of proinflammatory genes (by reverse transcription-polymerase chain reaction and chromatin immunoprecipitation), and recruitment of transcription factors and histone acetyltransferases/deacetylases to promoters of proinflammatory genes (egr-1, atf-3, inos, icam, il-6, and tnf-alpha) were determined in the pancreas during pancreatitis. Pentoxifylline did not reduce MEK1/2 phosphorylation but prevented the marked loss of serine/threonine phosphatase PP2A activity induced by taurocholate in vivo without affecting PP2B and PP2C activities. The rapid loss in PP2A activity induced by taurocholate in acinar cells was due to a decrease in cAMP levels that was prevented by pentoxifylline. Pentoxifylline also reduced the induction of early (egr-1, atf-3) responsive genes and abrogated the up-regulation of late (inos, icam, il-6, tnf-alpha) responsive genes and recruitment of transcription factors (nuclear factor kappaB and C/EBPbeta) and histone acetyltransferases to their gene promoters during pancreatitis. In conclusion, the beneficial effects of pentoxifylline--and presumably of other phosphodiesterase inhibitors--in this disease seem to be mediated by abrogating the loss of cAMP levels and PP2A activity as well as chromatin-modifying complexes very early during acute pancreatitis.

• Authors: Juan Sandoval, Javier Escobar, Javier Pereda, Natalia Sacilotto, José Luis Rodriguez, Luis Sabater, Luis Aparisi, Luis Franco, Gerardo López-Rodas, Juan Sastre
• Journal: The Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 331 Issue 2 Pg. 609-17 (Nov 2009) ISSN: 1521-0103 [Electronic] United States
• PMID: 19671881 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Inflammatory Agents
• Phosphodiesterase Inhibitors
• Tumor Necrosis Factor-alpha
• RNA
• Cyclic AMP
• Histone Acetyltransferases
• Extracellular Signal-Regulated MAP Kinases
• Mitogen-Activated Protein Kinases
• Phosphoprotein Phosphatases
• Cyclic Nucleotide Phosphodiesterases, Type 2
• Pentoxifylline

Topics

• Acute Disease
• Animals
• Anti-Inflammatory Agents
• Blotting, Western
• Cell Line
• Chromatin Immunoprecipitation
• Cyclic AMP (metabolism)
• Cyclic Nucleotide Phosphodiesterases, Type 2 (metabolism)
• Enzyme Activation (drug effects)
• Extracellular Signal-Regulated MAP Kinases (metabolism)
• Histone Acetyltransferases (metabolism)
• Inflammation (genetics)
• Male
• Mitogen-Activated Protein Kinases (metabolism)
• Pancreatitis (enzymology, genetics)
• Pentoxifylline (pharmacology)
• Phosphodiesterase Inhibitors (pharmacology)
• Phosphoprotein Phosphatases (metabolism)
• RNA (biosynthesis, genetics)
• Rats
• Rats, Wistar
• Reverse Transcriptase Polymerase Chain Reaction
• Tumor Necrosis Factor-alpha (biosynthesis)